Spironolactone benefits exercise tolerance in HFpEF

Spironolactone benefits exercise tolerance in HFpEF

(HealthDay)—For patients with heart failure with preserved ejection fraction (HFpEF) with an exercise-induced increase in the ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e'), spironolactone is associated with improved exercise capacity, according to a study published in the Oct. 25 issue of the Journal of the American College of Cardiology.

Wojciech Kosmala, M.D., Ph.D., from the Wroclaw Medical University in Poland, and colleagues conducted a randomized, placebo-controlled trial involving 150 subjects with exertional dyspnea. Patients were randomly allocated to six months of oral spironolactone or matching placebo. A total of 131 patients had completed therapy at follow-up (64 taking spironolactone and 67 taking placebo).

The researchers found that subjects had substantial exercise limitation at baseline. Improvements were seen in exercise capacity (P < 0.001), anaerobic threshold (P = 0.03), and oxygen uptake efficiency (P = 0.002) in the spironolactone group, with a reduction in E/e' (P < 0.001). A significant interaction was seen for spironolactone and the change in E/e' on peak oxygen uptake (P = 0.039).

"In patients with HFpEF and abnormal diastolic response to exertion, improvement in exercise E/e' mediates the beneficial effect of spironolactone on ," the authors write. "Identification of exercise-induced increase in left ventricular filling pressure in patients with HFpEF may define a subgroup with warranting trial of spironolactone."

Explore further

Long-term use of medication does not improve symptoms for heart failure patients

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Spironolactone benefits exercise tolerance in HFpEF (2016, October 18) retrieved 25 July 2021 from https://medicalxpress.com/news/2016-10-spironolactone-benefits-tolerance-hfpef.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments